financetom
Business
financetom
/
Business
/
Lemonade Stock Darts Higher On Q3 Earnings Beat, Strong Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lemonade Stock Darts Higher On Q3 Earnings Beat, Strong Guidance
Nov 5, 2025 7:58 AM

Lemonade Inc ( LMND ) shares are soaring Wednesday after the company reported third-quarter financial results and raised its full-year guidance.

LMND stock is at important technical levels. Check the fundamentals here.

What Happened: Lemonade reported revenue of $194.5 million for the third quarter, beating analyst estimates of $184.5 million, according to Benzinga Pro. The company reported a third-quarter loss of 51 cents per share, beating estimates for a loss of 73 cents per share.

Total revenue was up 42% on a year-over-year basis. Lemonade’s customer count grew 24% year-over-year to approximately 2.87 million. The aggregate annualized premium for customers increased by 30% to $1.16 billion, and premium per customer was $403 at the end of the quarter.

Lemonade ended the period with $1.06 billion in cash, cash equivalents and investments.

“More than half of new Car sales in the quarter came from existing Lemonade customers. This reinforces one of our core strategic advantages: the ability to drive CAC-free sales to our growing base of happy customers, improving unit economics and expanding wallet share,” the company said in a letter to shareholders.

“Looking ahead, we expect Car growth to continue to accelerate, fueled in part by TAM expansion from new state launches and increased brand / growth investment.”

What’s Next: Lemonade expects fourth-quarter revenue of $217 million to $222 million versus estimates of $213.82 million.

The company also raised its full-year revenue guidance. Lemonade now expects full-year revenue of $727 million to $732 million, up from a prior range of $710 million to $715 million. Analysts are looking for full-year revenue of $713.72 million, according to Benzinga Pro.

LMND Price Action: Lemonade shares were up 24.77% at $73.31 at the time of publication on Wednesday, according to Benzinga Pro.

Read Next:

Insulet, Uber And A Financial Stock On CNBC’s ‘Final Trades’

Image: Shutterstock.com

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved